Rusty Clayton, DO, serves as the Scientific Advisory Board Chair for Larimar Therapeutics. Dr. Clayton has more than 15 years of executive experience in pharmaceutical, biologics and medical device development and commercialization as a consultant in clinical development, medical affairs and regulatory affairs. Prior to becoming a consultant, he was the chief medical officer at Alcresta Therapeutics, a medical device company. While at Alcresta, Dr. Clayton led clinical development and medical affairs, overseeing the design and execution of pivotal clinical studies as well as developing a medical affairs capability in support of a new product launch. Prior to Alcresta Therapeutics, he was the senior vice president of research and development at Discovery Labs, a pharmaceutical and medical device company, where he led the scientific and regulatory efforts leading to the marketing authorization of Discovery’s first product. Dr. Clayton is a board-certified pediatric pulmonologist who practiced at St. Christopher’s Hospital for Children and the Children’s Hospital of Philadelphia prior to beginning his career in the pharmaceutical, biologics and medical device industry. Dr. Clayton received his DO from the Philadelphia College of Osteopathic Medicine.

Marshall Summar, MD, serves as Chief of the Division of Genetics and Metabolism, Director of the Rare Disease Institute and is the Margaret O’Malley Chair of Genetic Medicine at Children’s National Hospital (Children’s National). Well-known for his pioneering work in caring for children diagnosed with rare diseases, he joined Children’s National in 2010 from Vanderbilt University. In addition to guiding clinical research and treatment, Dr. Summar developed and launched the world’s first Rare Disease Institute (RDI) at Children’s National. The RDI is the first Clinical Center of Excellence designated by the National Organization for Rare Diseases (NORD) and focuses on building best clinical practices and diagnostic pathways for patients. With NORD and the FDA, Dr. Summar has worked to develop a patient-driven natural history platform employed by over 35 rare disease advocacy organizations. Dr. Summar is the current Board of Directors’ Chairman for NORD, the past president for the Society for Inherited Metabolic Disorders and serves on a number of rare disease-related advisory groups. He holds more than 60 patents and patent applications, has published more than 140 peer-reviewed research studies and has guided more than 25-funded research projects, with support from the National Institutes of Health (NIH), industry and independent philanthropists. Dr. Summar received his BS in molecular biology from Vanderbilt University and his MD from University of Tennessee Center for Health Sciences.

Giovanni Manfredi, MD, PhD, is the Finbar and Marianne Kenny Professor in Clinical and Research Neurology at Weill Cornell Medicine. He is also a Professor of Neuroscience and directs the graduate program in Neuroscience at Weill Cornell Medicine. Dr. Manfredi’s lab studies alterations of mitochondrial metabolism in neurodegenerative diseases, particularly amyotrophic lateral sclerosis and primary inherited mitochondrial encephalomyopathies. Dr. Manfredi has authored more than 100 publications focused in areas including neurodegenerative and mitochondrial diseases. Dr. Manfredi received his MD and PhD in anatomy and cell biology from Catholic University of the Sacred Heart in Rome, where he also completed a residency in neurology.

Marni J. Falk, MD, is Executive Director of the Mitochondrial Medicine Frontier Program at Children’s Hospital of Philadelphia (CHOP) and Professor in the Division of Human Genetics, Department of Pediatrics at University of Pennsylvania’s Perelman School of Medicine. Dr. Falk also serves as a principal investigator of a National Institutes of Health, pharmaceutical and philanthropic-funded translational laboratory group at CHOP that investigates the causes and global metabolic consequences of mitochondrial disease, as well as targeted therapies. She also directs multiple clinical treatment trials in mitochondrial disease patients. Dr. Falk has authored more than 100 publications in the areas of human genetics and mitochondrial disease. She received her BS in biology and MD from the George Washington University School of Medicine. In addition, Dr. Falk completed dual specialty training in the Pediatrics and Clinical Genetics residency program at Case Western Reserve University.

Mark Payne, MD, is a renowned scientist and practicing cardiovascular physician who brings a long-standing scientific focus on protein targeting to mitochondria and a dedication to treating cardiomyopathies of childhood, including Friedreich’s ataxia. He is the inventor of the original therapy for frataxin protein replacement in Friedreich’s ataxia and co-founded Chondrial Therapeutics, which became Larimar Therapeutics, Inc. He holds multiple patents on mitochondrial biology and repair. He is a tenured professor of pediatrics at Indiana University School of Medicine where he directs multiple NIH-funded training, clinical, and research programs as a principal investigator. Dr. Payne received his BS in natural sciences from Washington & Lee University, and his MD from the University of Texas at Houston. He performed his postdoctoral clinical and research training at Washington University in St. Louis. He is a Fellow of the American College of Cardiology and the American Academy of Pediatrics.